PHASQ stock plunged about 99.00% to $0.00 on 05 Mar 2026 during U.S. market hours on the PNK exchange, with 2,500 shares reported for the session. The steep drop follows continued illiquidity, a previous Chapter 11 filing and a notice that the company may be delisted, which pushed the quote near zero. Investors should note the stock’s 52-week high was $0.04 and the company still shows negative earnings with EPS -2.14. This report explains what moved the PHASQ stock price and offers an analyst view on the outlook.

PHASQ stock: Market plunge and today’s move

PHASQ stock fell roughly 99.00% intraday to $0.00 on 05 Mar 2026, reflecting minimal active trading and a previous close of $0.00010. The quote hit a day low and day high of $0.00, with average volume near 22,310 shares but today’s volume only 2,500. Market commentary flagged potential delisting risks, which explains the sharp price compression and extreme volatility in the PNK-listed security. MarketBeat reports the company has been marked as potentially delisted, a primary driver of today’s selling pressure.

PHASQ stock: Balance sheet and key financials

PhaseBio Pharmaceuticals, Inc. (PHASQ) lists cash per share at roughly $1.42 and shows negative net income with EPS -2.14, signaling ongoing losses. The company reports a current ratio near 1.75, but shareholders’ equity per share is negative at about -$3.16, underscoring solvency concerns. Given negligible market cap and enterprise value anomalies, standard valuation multiples are not meaningful for short-term price guidance.

PHASQ stock: Pipeline, catalysts and news links

PhaseBio’s lead candidate, bentracimab (PB2452), is a ticagrelor reversal agent in Phase III, and other programs include PB1046 and PB6440 in cardiopulmonary indications. Clinical readouts or regulatory actions remain the only realistic positive catalysts for PHASQ stock given its low trading price. Company details are available on the corporate site for pipeline context PhaseBio.

PHASQ stock: Trading, liquidity and technicals

Trading for PHASQ stock is extremely thin, with relative volume near 0.11 of average and 50-day and 200-day averages at $0.00 when rounded. Price averages (50-day $0.00, 200-day $0.00) and a 52-week low equal to today’s quote reflect effectively suspended market value. That illiquidity magnifies moves and raises execution risk for investors and funds.

PHASQ stock: Risks, delisting and regulatory exposure

Key risks for PHASQ stock include a potential delisting, Chapter 11 history from 2022, and ongoing cash burn tied to clinical development. With negative shareholders’ equity and irregular enterprise value metrics, the company faces heightened regulatory and financing risk that could further depress the public quote. Analysts typically classify the stock as speculative or distressed given these factors.

PHASQ stock: Meyka AI grade and analyst outlook

Meyka AI rates PHASQ with a score out of 100: 62.99 / 100 – Grade B – SUGGESTION: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s model flags weak liquidity and high operational risk but scores the company modestly for retained pipeline value and potential upside if clinical programs succeed. These grades are informational and not financial advice.

Final Thoughts

PHASQ stock is trading effectively at zero on the PNK exchange after a 99.00% decline on 05 Mar 2026, driven by delisting risk, limited liquidity, and legacy restructuring. Operationally, PhaseBio still lists clinical-stage assets such as bentracimab (PB2452) that could hold value, but current market dynamics make near-term recovery unlikely. Meyka AI’s forecast model projects $0.00 for PHASQ stock under its baseline scenario, compared with the prior quoted level near $0.00, indicating no material recovery in the model and reflecting extreme downside risk versus the 52-week high of $0.04. Forecasts are model-based projections and not guarantees. For traders and investors, the key takeaway is that PHASQ stock presents high execution risk, little liquidity and a binary catalyst profile where favorable clinical or corporate developments would be required to restore meaningful market value. We recommend monitoring trading notices, regulatory filings and official company updates before considering any exposure, and using small position sizing if one chooses to engage with this equity. Meyka AI-powered market analysis will continue to track major news and updates for PHASQ stock.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.